FOR IMMEDIATE RELEASE
CLC bio's profit grows more than 50% in 2011
Aarhus, Denmark -- January 5, 2011 -- Today, CLC bio is pleased to announce that the positive growth rates of recent
years have continued in 2011 with a 30% increase in software sales and a growth in operating profit of more than 50%
compared to 2010.
“Despite 2011 being the first year where we experienced our customers being impacted by the financial crisis in Europe
and the US, we still managed to achieve a 30% increase in software sales, compared to 2010. Furthermore, we had a 52%
increase in the number of organizations owning licenses for our software, rising to above 1500 in total." states CEO at
CLC bio, Thomas Knudsen, and continues, "We're still a positive cash flow company and have increased our annual profits
by more than 50% to more than 1 million USD - a significant factor in our continued investment in product development
and expanded market reach."
Director of Communications at CLC bio, Lasse Görlitz, adds, "Our growth is evidenced throughout the company, with the
number of employees increasing in 2011 by 34%. Looking behind the overall sales figures we're extremely pleased to see a
doubling in installations of our enterprise platform, as well as helping our third-party collaborators starting to
generate revenue through our open platform - an area we anticipate will grow substantially in 2012!"
CLC bio is a privately owned company, primarily funded by local investors and successfully built without venture capital
since January 2005. CLC bio is based in Aarhus, Denmark. CLC bio exports 98% of its software to organizations in
countries outside of Denmark, and 45% of the sales are generated in USA.
ends